Evidence map›Paper›PMID 29573052›Full record

ArticleHuman mutation2018

A homozygous variant disrupting the PIGH start-codon is associated with developmental delay, epilepsy, and microcephaly.

Alistair T Pagnamenta, Yoshiko Murakami, Consuelo Anzilotti, Hannah Titheradge, Adam J Oates, Jenny Morton, DDD Study, Taroh Kinoshita, Usha Kini, Jenny C Taylor

Open access · hybridAbstract read
In one paragraph

Article in Human mutation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Cells · 2020
    Article
  8. Review
  9. Efficient Gene Silencing by Adenine Base Editor-Mediated Start Codon Mutation.Molecular therapy : the journal of the American Society of Gene Therapy · 2020
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Alistair T PagnamentaNational Institute for Health Research Oxford Biomedical Research Centre, Wellcome Centre for Human Genetics, University of Oxford, Oxford, Oxfordshire, UK.ORCID 0000-0001-7334-0602
Yoshiko MurakamiYabumoto Department of Intractable Disease Research, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID 0000-0002-4870-5734
Consuelo AnzilottiWeatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Hannah TitheradgeWest Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's NHS Foundation Trust, Birmingham Women's Hospital, Mindelsohn Way, Edgbaston, Birmingham, UK.
Adam J OatesRadiology Department, Birmingham Children's Hospital, Birmingham, UK.
Jenny MortonWest Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's NHS Foundation Trust, Birmingham Women's Hospital, Mindelsohn Way, Edgbaston, Birmingham, UK.
DDD StudyWellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Taroh KinoshitaYabumoto Department of Intractable Disease Research, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Usha KiniOxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Jenny C TaylorNational Institute for Health Research Oxford Biomedical Research Centre, Wellcome Centre for Human Genetics, University of Oxford, Oxford, Oxfordshire, UK.
Centre for Human Genetics · GBBirmingham Women's Hospital · GBBirmingham Children's Hospital · GBJohn Radcliffe Hospital · GBOsaka International University · JPOxford University Hospitals NHS Trust · GBWellcome Sanger Institute · GB

Funding

Wellcome TrustWellcome Trust 090532/Z/09/ZWellcome Trust WT098051
6 · The paper itself

Abstract

Defective glycosylphosphatidylinositol (GPI)-anchor biogenesis can cause a spectrum of predominantly neurological problems. For eight genes critical to this biological process, disease associations are not yet reported. Scanning exomes from 7,833 parent-child trios and 1,792 singletons from the DDD study for biallelic variants in this gene-set uncovered a rare PIGH variant in a boy with epilepsy, microcephaly, and behavioral difficulties. Although only 2/2 reads harbored this c.1A > T transversion, the presence of ∼25 Mb autozygosity at this locus implied homozygosity, which was confirmed using Sanger sequencing. A similarly-affected sister was also homozygous. FACS analysis of PIGH-deficient CHO cells indicated that cDNAs with c.1A > T could not efficiently restore expression of GPI-APs. Truncation of PIGH protein was consistent with the utilization of an in-frame start-site at codon 63. In summary, we describe siblings harboring a homozygous c.1A > T variant resulting in defective GPI-anchor biogenesis and highlight the importance of exploring low-coverage variants within autozygous regions.

Indexed as

AdolescentAnimalsChildChild, PreschoolCodon, InitiatorCricetinaeDevelopmental DisabilitiesEpilepsyExomeFemaleGlycosylphosphatidylinositolsHumansMaleMembrane ProteinsMicrocephalyMutationCodon, InitiatorGlycosylphosphatidylinositolsMembrane ProteinsPIGH protein, humandevelopmental delayexomeGPI-anchor biogenesismicrocephalyphosphatidylinositol N-acetylglucosaminyltransferasePIGH

Identifiers

PMID29573052
PMCPMC6001798
OpenAlexW2793019556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.